普托马尼治疗结核病的系统综述
该系统综述评估了含普托马尼方案治疗结核病的疗效与安全性,共纳入8项研究。在耐利福平及高度耐药结核中,含普托马尼方案显示良好治疗结局,但普托马尼-莫西沙星-吡嗪酰胺方案因严重肝毒性不良事件(包括3例死亡)提前终止,且利奈唑胺相关毒性常见。
要点
- 普托马尼在耐利福平和高度耐药结核中可能起重要作用
- 普托马尼-莫西沙星-吡嗪酰胺方案因严重肝毒性(4%患者,含3例死亡)提前终止
- 高度耐药结核用普托马尼-贝达喹啉-利奈唑胺治疗6个月后90%获良好结局,但利奈唑胺毒性常见
核心结论
- 证据提示普托马尼在耐利福平和高度耐药结核中具有重要作用。
- 需要开展将普托马尼与现有核心及伴随药物进行比较的试验以进一步明确其作用。
研究设计与样本
- 系统综述,检索Pubmed、clinicaltrials.gov和Cochrane图书馆,纳入8项定量研究。
- 纳入研究包括4项关于2周早期杀菌活性的随机对照试验、3项含随机利福平敏感结核组和单臂利福平耐药组的研究(2项关于8周杀菌活性,1项关于治疗结束时结局)、1项高度耐药结核单臂治疗结束时结局研究。
主要发现
- 在利福平敏感结核中,普托马尼-莫西沙星-吡嗪酰胺方案在第0-2天、0-56天和7-56天的菌落形成单位每日变化及培养转阴时间上优于标准治疗(风险比:1.7;95%CI 1.1-2.7),但在一项研究中治疗结束时未显示优势。
- 该研究因严重肝毒性不良事件提前终止,普托马尼-莫西沙星-吡嗪酰胺组4%(95%CI 2-8)患者发生严重肝毒性不良事件(包括3例死亡),对照组无发生。
- 在无并发症的耐利福平结核患者中,普托马尼-莫西沙星-吡嗪酰胺治疗结束时良好结局比例为91%(95%CI 59-100)。
- 在高度耐药结核患者中,普托马尼-贝达喹啉-利奈唑胺治疗6个月后良好结局比例为90%(95%CI 83-95),但利奈唑胺相关毒性常见。
- 未报告普托马尼获得性耐药。
临床怎么用
- 普托马尼可用于耐利福平和高度耐药结核的治疗方案,但需密切监测肝毒性和利奈唑胺相关毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes of treatment of tuberculosis patients with regimens including pretomanid have not yet been systematically reviewed. OBJECTIVES: To appraise existing evidence on efficacy and safety of pretomanid in tuberculosis. DATA SOURCES: Pubmed, clinicaltrials.gov. and Cochrane library. STUDY ELIGIBILITY CRITERIA: Quantitative studies presenting original data on clinical efficacy or safety of pretomanid. PARTICIPANTS: Patients with tuberculosis. INTERVENTIONS: Treatment with pretomanid or pretomanid-containing regimens in minimum one study group. METHODS: Two authors independently extracted data and assessed risk of bias. Data on efficacy (early bactericidal activity, bactericidal activity, end-of-treatment outcomes and acquired resistance) and safety were summarized in tables. Mean differences in efficacy outcomes between regimens across studies were calculated. RESULTS: Eight studies were included; four randomized controlled trials on 2-week early bactericidal activity in rifampicin-susceptible tuberculosis, three trials with randomized rifampicin-susceptible tuberculosis arms and a single rifampicin-resistant tuberculosis arm (two on 8-week bactericidal activity, one on end-of-treatment outcomes), one single-arm trial with end-of-treatment outcomes in highly resistant tuberculosis. Activity of pretomanid-moxifloxacin-pyrazinamide was superior to standard treatment on daily change in colony-forming units at days 0-2, 0-56 and 7-56 and time to culture conversion in rifampicin-susceptible tuberculosis (hazard ratio: 1.7; 95% CI 1.1-2.7), but not at end of treatment in one study. This study was stopped due to serious hepatotoxic adverse events, including three deaths, in 4% (95% CI 2-8) patients on pretomanid-moxifloxacin-pyrazinamide and none in controls. In patients with uncomplicated rifampicin-resistant tuberculosis on pretomanid-moxifloxacin-pyrazinamide treatment, 91% (95% CI 59-100) had favourable end-of-treatment outcomes. In patients with highly resistant tuberculosis, 90% (95% CI 83-95) on pretomanid-bedaquiline-linezolid had favourable outcomes six months after treatment, but linezolid-related toxicity was frequent. No acquired resistance to pretomanid was reported. CONCLUSIONS: Evidence suggests an important role for pretomanid in rifampicin-resistant and highly resistant tuberculosis. Trials comparing pretomanid to existing core and companion drugs are needed to further define that role.
引用
- Gils T, Lynen L, de Jong BC, et al. Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect. 2021. PMID: 34400340. doi:10.1016/j.cmi.2021.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。